NO20053592L - Vann opploslige fenylpyridazinderivater og medikamenter inneholdende disse. - Google Patents

Vann opploslige fenylpyridazinderivater og medikamenter inneholdende disse.

Info

Publication number
NO20053592L
NO20053592L NO20053592A NO20053592A NO20053592L NO 20053592 L NO20053592 L NO 20053592L NO 20053592 A NO20053592 A NO 20053592A NO 20053592 A NO20053592 A NO 20053592A NO 20053592 L NO20053592 L NO 20053592L
Authority
NO
Norway
Prior art keywords
water soluble
drugs containing
phenylpyridazine derivatives
derivatives
salt
Prior art date
Application number
NO20053592A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053592D0 (no
Inventor
Hiromichi Shigyo
Seiichi Sato
Yoshinori Kyotani
Tomoyuki Koshi
Takahiro Kitamura
Hideo Yoshizaki
Kyoko Yasuoka
Shunji Takemura
Junko Totsuka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20053592D0 publication Critical patent/NO20053592D0/no
Publication of NO20053592L publication Critical patent/NO20053592L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20053592A 2003-03-18 2005-07-25 Vann opploslige fenylpyridazinderivater og medikamenter inneholdende disse. NO20053592L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003073403 2003-03-18
PCT/JP2004/003487 WO2004083188A1 (ja) 2003-03-18 2004-03-16 水溶性フェニルピリダジン誘導体及びこれを含有する医薬

Publications (2)

Publication Number Publication Date
NO20053592D0 NO20053592D0 (no) 2005-07-25
NO20053592L true NO20053592L (no) 2005-11-30

Family

ID=33027793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053592A NO20053592L (no) 2003-03-18 2005-07-25 Vann opploslige fenylpyridazinderivater og medikamenter inneholdende disse.

Country Status (13)

Country Link
US (1) US7211577B2 (ja)
EP (1) EP1604984A1 (ja)
JP (1) JPWO2004083188A1 (ja)
KR (1) KR20050113627A (ja)
CN (1) CN1759103A (ja)
AU (1) AU2004221966A1 (ja)
BR (1) BRPI0408359A (ja)
CA (1) CA2518227A1 (ja)
MX (1) MXPA05009972A (ja)
NO (1) NO20053592L (ja)
RU (1) RU2005132167A (ja)
TW (1) TW200510335A (ja)
WO (1) WO2004083188A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
US20090131443A1 (en) * 2005-10-28 2009-05-21 Kowa Co., Ltd. Method for prevention and/or treatment of rheumatoid arthritis
LT2953952T (lt) * 2013-02-07 2017-08-25 Merck Patent Gmbh Makrocikliniai piridazinono dariniai
RS56331B1 (sr) * 2013-02-07 2017-12-29 Merck Patent Gmbh Derivati piridazinon-amida
FR3103701B1 (fr) * 2019-11-28 2021-11-26 Inst Nat Sante Rech Med Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206496A1 (es) 1972-07-03 1976-07-30 Riker Laboratories Inc Procedimiento para la preparacion de 2-fenoxi-4-nitro-alquil o haloalquilsulfonanilidas
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
FI91062C (fi) 1988-12-28 1994-05-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
AU699148B2 (en) 1995-08-10 1998-11-26 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
ATE271547T1 (de) 1997-03-14 2004-08-15 Merck Frosst Canada Inc Pyridazinone als inhibitoren von cyclooxygenase-2
EP1007515A1 (en) 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
ATE319691T1 (de) 1997-08-22 2006-03-15 Abbott Lab Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
RU2209813C2 (ru) * 1997-11-19 2003-08-10 Кова Ко., Лтд. Производные пиридазина, лекарственные средства на их основе и способ лечения артрита
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
CZ300570B6 (cs) 1998-10-27 2009-06-17 Abbott Laboratories Inhibitory biosyntézy prostaglandin endoperoxid H synthasy
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6861428B2 (en) * 2001-09-26 2005-03-01 Kowa Co., Ltd. Water-soluble phenylpyridazine compounds and compositions containing the same
CN1304379C (zh) * 2001-09-26 2007-03-14 兴和株式会社 水溶性苯基哒嗪衍生物及含有该衍生物的药物
NZ541064A (en) 2003-03-07 2007-09-28 Kowa Co Benzofuran derivative

Also Published As

Publication number Publication date
EP1604984A1 (en) 2005-12-14
CA2518227A1 (en) 2004-09-30
AU2004221966A1 (en) 2004-09-30
US20060142292A1 (en) 2006-06-29
KR20050113627A (ko) 2005-12-02
BRPI0408359A (pt) 2006-03-21
NO20053592D0 (no) 2005-07-25
WO2004083188A1 (ja) 2004-09-30
CN1759103A (zh) 2006-04-12
MXPA05009972A (es) 2005-11-04
TW200510335A (en) 2005-03-16
US7211577B2 (en) 2007-05-01
RU2005132167A (ru) 2006-05-10
JPWO2004083188A1 (ja) 2006-06-22

Similar Documents

Publication Publication Date Title
NO20054852L (no) GFAT inhibitorer
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
NO20035210D0 (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
GEP20074152B (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
UA94065C2 (en) Dihydropseudoerythromycin derivatives
NO20073551L (no) Nikotinacetylkolinreseptorligander
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
NO20070570L (no) Forbindelser.
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
NO20050087L (no) N-benzoylureido-kanelsyrederivater, fremgangsmate for fremstilling og anvendelse av disse
ATE433969T1 (de) Pyrimidine verbindungen
NO20062453L (no) Tiozolidinoner, fremstilling og anvendelse derav som legemidler
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
NO20071616L (no) Benzoksazin- og kinoksalinderivater og anvendelser
WO2004062562A3 (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
NO20053592L (no) Vann opploslige fenylpyridazinderivater og medikamenter inneholdende disse.
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
EP1571144A4 (en) HYDROXYALKYLATED CYCLIC DEDIAMINE COMPOUND

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application